At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 84 enrolled
Drug / intervention
SHP626 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Multiple Oral Doses of SHP626 in Overweight and Obese Adult Subjects
In Brief
A Phase 1 clinical trial evaluating SHP626 and Placebo for Non-Alcoholic Steatohepatitis. Completed, enrolled 84 participants across 1 site.
Detailed Summary
This study will investigate the safety and tolerability of daily dosing regimens of SHP626 in overweight and obese adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Alcoholic Steatohepatitis
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 2014
Enrollment StartJan 2015
Primary CompletionJun 2015
TodayJul 2026
First PostedNov 11, 2014
Enrollment StartJan 19, 2015
Primary CompletionJun 19, 2015
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 11.6 years ago
Interventions
SHP626drug
Placebodrug